Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots

被引:145
作者
Judd, A
Parry, J
Hickman, M
McDonald, T
Jordan, L
Lewis, K
Contreras, M
Dusheiko, G
Foster, G
Gill, N
Kemp, K
Main, J
Murray-Lyon, L
Nelson, M
机构
[1] Univ London Imperial Coll Sci Technol & Med, Ctr Res Drugs & Hlth Behav, Fac Med, Dept Social Sci & Med, London W6 8RP, England
[2] Cent Publ Hlth Lab, Sexually Transmitted & Bloodborne Virus Lab, London NW9 5HT, England
[3] Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England
[4] Natl Blood Serv London & S E, London, England
[5] UCL Royal Free & Univ Coll, Sch Med, London, England
[6] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England
[7] Camden & Islington NHS Commun Trust Drug Serv, London, England
[8] Charing Cross Hosp, London, England
[9] Chelsea & Westminster Hosp, London, England
关键词
antibody; assay; dried blood spots; HCV; hepatitis C; oral fluid;
D O I
10.1002/jmv.10463
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Oral fluid testing is an effective alternative to serum antibody testing for surveillance of human immunodeficiency virus (HIV) and hepatitis B infections, and is being extended to hepatitis C infections. The objective of this study was to determine and compare the sensitivity and specificity of a modified commercial assay for the detection of antibody to hepatitis C virus (anti-HCV) in oral fluids collected by two different oral fluid collection devices (the Epitope OraSure(TM) and Sarstedt Salivette(TM)) and in dried fingerprick blood spots. In this study, 253 anti-HCV seropositive patients and 394 blood donors (all anti-HCV negative) were recruited between August 2000 and January 2001. Each participant provided oral fluid specimens by OraSure and Salivette, and at least one dried blood spot. Serum specimens were collected from the patients whenever possible. For those injecting drug users who did not provide a serum specimen, HCV status was established on the basis of previous testing. All the nonserum samples were tested for the presence of anti-HCV, using a modified Ortho HCV 3.0 SAVe enzyme-linked immunosorbent assay (ELISA) protocol. The recommended preliminary cutoffs for the modified ELISA were suboptimal. Further, the sensitivity, specificity, and positive and negative predictive values could be improved by varying the cutoff and taking into account the likely prevalence of HCV in the population under investigation. For instance, given a population with a 50% prevalence of anti-HCV, the optimal sensitivities of the modified assay on OraSure, Salivette, and dried blood spots were 92%, 83%, and virtually 100%, respectively, in contrast to 83%, 59%, and 99% using the preliminary cutoffs. The respective optimal specificities were 99%, 93%, and 100%. In conclusion, oral fluids collected by the OraSure device provide an extremely useful method to conduct public health surveillance of not only HIV, but also hepatitis C, among injecting drug users. In addition, dried blood spot specimens may be useful for surveillance and could be employed as a first line diagnostic specimen. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 27 条
[1]   Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature [J].
Abe, K ;
Konomi, N .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :3070-3072
[2]   ESTIMATES OF DISEASE INCIDENCE IN WOMEN BASED ON ANTENATAL OR NEONATAL SEROPREVALENCE DATA - HIV IN NEW-YORK-CITY [J].
ADES, AE ;
MEDLEY, GF .
STATISTICS IN MEDICINE, 1994, 13 (18) :1881-1894
[3]   Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey [J].
Allwright, S ;
Bradley, F ;
Long, J ;
Barry, J ;
Thornton, L ;
Parry, JV .
BRITISH MEDICAL JOURNAL, 2000, 321 (7253) :78-82
[4]  
[Anonymous], HEP C STRAT ENGL
[5]   Assessment of a hepatitis C virus antibody assay in saliva for epidemiological studies [J].
Bello P.-Y. ;
Pasquier C. ;
Gourney P. ;
Puel J. ;
Izopet J. .
European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17 (8) :570-572
[6]   Detection of antibodies against hepatitis C virus in saliva: a marker of viral replication [J].
Cameron, SO ;
Wilson, KS ;
Good, T ;
McMenamin, J ;
McCarron, B ;
Pithie, A ;
Fox, R .
JOURNAL OF VIRAL HEPATITIS, 1999, 6 (02) :141-144
[7]   The Australian Study of HIV and Injecting Drug Use .2. Predicting exposure to hepatitis C and hepatitis B [J].
Carruthers, SJ ;
Loxley, WM ;
Phillips, M ;
Bevan, JS .
DRUG AND ALCOHOL REVIEW, 1997, 16 (03) :215-220
[8]  
Derricott J., 1999, SAFER INJECTING BRIE
[9]  
Elsana S, 1998, J MED VIROL, V55, P24, DOI 10.1002/(SICI)1096-9071(199805)55:1&lt
[10]  
24::AID-JMV5&gt